A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression

Trial Profile

A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms Illuminate
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2017 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry
    • 27 Oct 2017 Full results from this trial were presented at a scientific meeting in Washington, D.C., being held October 23-28, 2017, according to a Sunovion Pharmaceuticals media release
    • 27 Oct 2017 Post-hoc analysis of this trial presented in a Sunovion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top